- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 29
- States / cities
- Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,539
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease, Healthy
- Interventions
- Raclopride
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypoglycemia, Type 1 Diabetes
- Interventions
- Dasiglucagon
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fort Worth, Texas
- Conditions
- Breast Neoplasms
- Interventions
- pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Lenvatinib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 26
- States / cities
- Fresno, California • San Marcos, California • Aurora, Colorado + 22 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 22 more
- Conditions
- Non Small Cell Lung Cancer, NSCLC
- Interventions
- CoreDx Pulmonary Mini-Forceps
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Essential Tremor, Parkinson's Disease
- Interventions
- DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
- Other
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
- Conditions
- Chronic Kidney Disease Stage 5
- Interventions
- Pegloticase
- Drug
- Lead sponsor
- Savient Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
- Interventions
- rezatapopt, pembrolizumab
- Drug
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Psoriasis
- Interventions
- Calcipotriene 0.005% Foam
- Drug
- Lead sponsor
- Mayne Pharma International Pty Ltd
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- San Diego, California • Ormond Beach, Florida • Tampa, Florida + 6 more
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Anemia
- Interventions
- Roxadustat
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 4
- States / cities
- Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Dupilumab, PD-1/PD-L1 blockade, Anakinra
- Drug
- Lead sponsor
- Thomas Marron
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- Ulevostinag, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Interventions
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Drug
- Lead sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Parkinson Disease
- Interventions
- AAV2-GDNF gene therapy, control surgery
- Drug · Procedure
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
- Conditions
- Mycosis Fungoides
- Interventions
- Pembrolizumab administered using the Sofusa® DoseConnect™
- Combination Product
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Parkinson Disease, Deep Brain Stimulation, Apathy
- Interventions
- Deep Brain Stimulation
- Device
- Lead sponsor
- Nora Vanegas
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17 participants
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Myelodysplastic Syndrome
- Interventions
- ON 01910.Na
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Retifanlimab, Tuparstobart, Verzistobart
- Procedure · Biological · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Parkinson's Disease
- Interventions
- Oxaloacetate (OAA), Placebo
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Acute Coronary Syndrome
- Interventions
- vicagrel Capsules, Clopidogrel Tablets
- Drug
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Kansas City, Missouri